Literature DB >> 22048691

The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan.

Seiji Kawa1, Masanori Onda, Mitchell Ho, Robert J Kreitman, Tapan K Bera, Ira Pastan.   

Abstract

HA22-LR is a recombinant immunotoxin for the treatment of B-cell malignancies that contains the Fv portion of an anti-CD22 antibody fused to a functional portion of Pseudomonas exotoxin A. In the present study, we attempted to improve this molecule. First, we produced a single-chain version of HA22-LR (scdsFv-HA22-LR) in which a peptide linker was introduced between the disulfide-linked light and heavy chains to enable production via single fermentation. No difference in cytotoxic activity was observed between scdsFv-HA22-LR and prototype HA22-LR. Next, we attempted to increase the affinity of scdsFv-HA22-LR by using alanine scanning mutagenesis of complementarity determining regions (CDRs) to assess the specific contribution of each CDR residue to the antigen binding. We found that mutation of asparagine 34 in VLCDR1, which is located at the VL/VH interface, to alanine (N34A) caused a substantial increase in affinity and activity. Estimated KD values measured by fluorescence-activated cell sorting were lowered by 10-fold: 0.056 nM in the N34A mutant compared to 0.58 nM in wild type (WT). Cell viability assays of CD22-positive B-cell lymphoma and leukemia cell lines showed that the N34A mutant had increased cytotoxicity ranging from ~2 (HAL-1, IC 50(WT): 2.37 ± 0.62 ng/ml, IC 50(N34A): 1.32 ± 0.41 ng/ml) to 10 (SUDHL-6, IC 50(WT): 0.47 ± 0.090 ng/ml, IC 50(N34A): 0.048 ± 0.018 ng/ml)-fold compared to WT immunotoxin. The present study suggests that the N34A mutant of scdsFv-HA22-LR could have important consequences in a clinical setting.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22048691      PMCID: PMC3225852          DOI: 10.4161/mabs.3.5.17228

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   6.440


  40 in total

1.  Antibody multispecificity mediated by conformational diversity.

Authors:  Leo C James; Pietro Roversi; Dan S Tawfik
Journal:  Science       Date:  2003-02-28       Impact factor: 47.728

2.  Recombinant immunotoxins in the treatment of cancer.

Authors:  Ira Pastan; Richard Beers; Tapan K Bera
Journal:  Methods Mol Biol       Date:  2004

Review 3.  Selection and evolution of high-affinity human anti-viral antibodies.

Authors:  C F Barbas; D R Burton
Journal:  Trends Biotechnol       Date:  1996-07       Impact factor: 19.536

4.  Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection.

Authors:  R Schier; J Bye; G Apell; A McCall; G P Adams; M Malmqvist; L M Weiner; J D Marks
Journal:  J Mol Biol       Date:  1996-01-12       Impact factor: 5.469

5.  Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain.

Authors:  N M Low; P H Holliger; G Winter
Journal:  J Mol Biol       Date:  1996-07-19       Impact factor: 5.469

6.  Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.

Authors:  Giuliana Salvatore; Richard Beers; Inger Margulies; Robert J Kreitman; Ira Pastan
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

7.  Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.

Authors:  R J Kreitman; W H Wilson; J D White; M Stetler-Stevenson; E S Jaffe; S Giardina; T A Waldmann; I Pastan
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

8.  Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.

Authors:  Hyun-Soo Cho; Karen Mason; Kasra X Ramyar; Ann Marie Stanley; Sandra B Gabelli; Dan W Denney; Daniel J Leahy
Journal:  Nature       Date:  2003-02-13       Impact factor: 49.962

9.  Structural basis of a conserved idiotope expressed by an autoreactive human B cell lymphoma. Evidence that a VH CDR3 mutation alters idiotypy and specificity.

Authors:  L S Reidl; D F Friedman; J Goldman; R R Hardy; L C Jefferies; L E Silberstein
Journal:  J Immunol       Date:  1991-11-15       Impact factor: 5.422

10.  Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis.

Authors:  D E Yelton; M J Rosok; G Cruz; W L Cosand; J Bajorath; I Hellström; K E Hellström; W D Huse; S M Glaser
Journal:  J Immunol       Date:  1995-08-15       Impact factor: 5.422

View more
  7 in total

Review 1.  Immunotoxins for leukemia.

Authors:  Alan S Wayne; David J Fitzgerald; Robert J Kreitman; Ira Pastan
Journal:  Blood       Date:  2014-02-27       Impact factor: 22.113

2.  In silico analysis of STX2a-PE15-P4A8 chimeric protein as a novel immunotoxin for cancer therapy.

Authors:  Maryam Keshtvarz; Jafar Salimian; Jafar Amani; Masoumeh Douraghi; Ehsan Rezaie
Journal:  In Silico Pharmacol       Date:  2021-02-10

3.  Facile Affinity Maturation of Antibody Variable Domains Using Natural Diversity Mutagenesis.

Authors:  Kathryn E Tiller; Ratul Chowdhury; Tong Li; Seth D Ludwig; Sabyasachi Sen; Costas D Maranas; Peter M Tessier
Journal:  Front Immunol       Date:  2017-09-04       Impact factor: 7.561

4.  Improvement in affinity and thermostability of a fully human antibody against interleukin-17A by yeast-display technology and CDR grafting.

Authors:  Wei Sun; Zhaona Yang; Heng Lin; Ming Liu; Chenxi Zhao; Xueying Hou; Zhuowei Hu; Bing Cui
Journal:  Acta Pharm Sin B       Date:  2019-02-22       Impact factor: 11.413

5.  Let's Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia.

Authors:  Dalma Deak; Cristina Pop; Alina-Andreea Zimta; Ancuta Jurj; Alexandra Ghiaur; Sergiu Pasca; Patric Teodorescu; Angela Dascalescu; Ion Antohe; Bogdan Ionescu; Catalin Constantinescu; Anca Onaciu; Raluca Munteanu; Ioana Berindan-Neagoe; Bobe Petrushev; Cristina Turcas; Sabina Iluta; Cristina Selicean; Mihnea Zdrenghea; Alina Tanase; Catalin Danaila; Anca Colita; Andrei Colita; Delia Dima; Daniel Coriu; Hermann Einsele; Ciprian Tomuleasa
Journal:  Front Immunol       Date:  2019-12-20       Impact factor: 7.561

6.  Affinity Maturation of Monoclonal Antibody 1E11 by Targeted Randomization in CDR3 Regions Optimizes Therapeutic Antibody Targeting of HER2-Positive Gastric Cancer.

Authors:  Bong-Kook Ko; Soyoung Choi; Lei Guang Cui; Young-Ha Lee; In-Sik Hwang; Kyu-Tae Kim; Hyunbo Shim; Jong-Seo Lee
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

7.  Affinity improvement of a therapeutic antibody by structure-based computational design: generation of electrostatic interactions in the transition state stabilizes the antibody-antigen complex.

Authors:  Masato Kiyoshi; Jose M M Caaveiro; Eri Miura; Satoru Nagatoishi; Makoto Nakakido; Shinji Soga; Hiroki Shirai; Shigeki Kawabata; Kouhei Tsumoto
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.